ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants

Inclusion Criteria: * Experienced Egyptian participants with HCV GT4 infection who had failed prior DAA treatments \[SOF/DCV or SOF/SMV or SOF/pegylated interferon/RBV or SOF/RBV\] * Fibrosis-4 score in non-cirrhotic participants is \<1.45-3.25: (None or moderate fibrosis) * Fibrosis-4 score in cirrhotic participants is \>3.25: (Advanced fibrosis or cirrhosis) Exclusion Criteria: * HCV coinfected with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) * had any liver disease other than chronic HCV GT4 infection. * had a history of liver decompensation * serum a-fetoprotein (AFP) \> 100 ng/ml * evidence of hepatocellular carcinoma * major severe illness such as respiratory, renal, heart failure or autoimmune disease * non-compliance with treatment.